Using DOACs for Valvular Atrial Fibrillation - Frankly Speaking Ep 249
b'Credits: 0.25 AMA PRA Category 1 Credit\\u2122\\n\\xa0\\nCME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-249\\n\\xa0\\nOverview: For non-valvular atrial fibrillation, physicians, patients, and guideline organizations all prefer direct oral anticoagulants (DOACs) over vitamin K antagonists, such as warfarin, for thromboembolic prophylaxis. For those with valvular atrial fibrillation, the data for safety and efficacy have been limited because randomized trials comparing DOACs to warfarin often exclude patients with valvular atrial fibrillation. Join us to explore new data that shed light on the use of DOACs in valvular atrial fibrillation.\\n\\xa0\\nEpisode resource links:\\nDawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. Ann Intern Med. 2021;174(7):910-919.\\nGuest: Alan Ehrlich MD, FAAFP\\n\\xa0\\nMusic Credit: Richard Onorato'